NICE confirms rejection of Gen-Probe and Progenika hypercholesterolaemia tests
This article was originally published in Clinica
Molecular diagnostics companies Gen-Probe and Progenika were dealt a blow by the UK’s National Institute for Health and Clinical Excellence (NICE) when the latter published final guidance recommending against routine use of Gen-Probe’s Elucigene FH20 and Progenika’s LIPOchip for either confirmation or cascade screening of familial hypercholesterolaemia (FH).
You may also be interested in...
Companies across Europe are dealing with new challenges stemming from the coronavirus outbreak, particularly with supply issues due to increased demand. This article details the responses of five consumer health players in the region: Reckitt Benckiser, Zentiva, Vitabiotics, Alliance Pharma and BioGaia.
As the global shut-down caused by the coronavirus pandemic continues, sponsors are rushing to adapt clinical trials that can move to partial or completely remote monitoring, allowing patients to remain in their homes but continue to participate in studies. And the outbreak may have another silver lining for the biopharma industry, a chance to rebuild its reputation.
The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.